Company profile for Ikarovec

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ikarovec was formed as a spin-out from the biotechnology company Quethera, which was acquired by Astellas Pharmaceuticals in 2018. It is a pre-clinical phase gene therapy company. The company has an early-stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms), and ocular hypertension.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Innovation Centre, Norwich, NR4 7GJ, GB
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/contents/view_breaking-news/2023-06-01/rentschler-biopharma-ikarovec-partner-on-gene-therapies-for-ophthalmic-disease/?widget=listSection

CONTRACT PHARMA
01 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty